This page tracks new and upcoming treatment options for hidradenitis suppurativa (HS). What’s in development? What’s promising? What’s available soon? Current topics include SBT-77-710, orismilast, PDE4 inhibitors, PTM-001, lutikizumab (ABT-981), secukinumab, izokibep, spesolimab, sonelokimab, eltrekibart (LY3041658), SAR442970, SAR444656 (KT-474), povorcitinib (INCB054707), amlitelimab, microbiota transplant therapy, zunsemetinib (ATI-450), rinvoq, and more.
- 3 months ago
News
- Enhancing specific immune cells that suppress inflammation can effectively treat HS Apr 30, 2025
- UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of hidradenitis suppurativa Jan 10, 2024
- Lutikizumab Shows Positive Results in Phase 2 Hidradenitis Suppurativa Trial, Advances to Phase 3 Jan 8, 2024
- Heat Shock Protein 90 Inhibition with RGRN-305 Shown to Help Treat HS Dec 8, 2023
- Kymera Therapeutics Announces Positive Phase 1 Trial Results for KT-474 for Hidradenitis Suppurativa (HS) Nov 13, 2023
- FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade Oct 31, 2023
- MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa Oct 15, 2023
- UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023 Oct 13, 2023
- Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Cell Therapy at Symposium on Hidradenitis Suppurativa Advances Oct 13, 2023
- Scientists unearth potential new target for treating debilitating skin disease hidradenitis suppurativa Sep 26, 2023
- MC2 Therapeutics bags license rights for hidradenitis suppurativa drug Sep 25, 2023
- Acelyrin’s Lead Asset Izokibep Fails in Late-Stage Hidradenitis Suppurativa Trial Sep 12, 2023
- Genetic Variants Associated with Hidradenitis Suppurativa Aug 27, 2023
- AbbVie doses first patient in phase 3 study of Rinvoq in hidradenitis suppurativa Jul 26, 2023
- Researchers Discover Genetic Locations for Increased Risk of Hidradenitis Suppurativa Jul 26, 2023
- MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa Jun 25, 2023
- Aclaris Therapeutics Announces Preliminary Topline Data from 12-Week Phase 2a Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Hidradenitis Suppurativa Mar 6, 2023
Research
- Hidradenitis Suppurativa: An Understanding of Genetic Factors and Treatment Feb 1, 2024
- Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study Jan 23, 2024
- Hidradenitis suppurativa: a review with new insights into disease mechanisms and potential future treatments Jan 23, 2024
- Pathological and Therapeutical Implications of Pyroptosis in Psoriasis and Hidradenitis Suppurativa: A Narrative Review Jan 11, 2024
- Factors Affecting Treatment Selection Among Patients With Hidradenitis Suppurativa Jan 10, 2024
- An Atlas of the Hidradenitis Suppurativa Transcriptome: implications for both the diagnosis of HS and for developing new targeted therapies Jan 6, 2024
- Topical and Intralesional Therapies for Hidradenitis Suppurativa: A Systematic Literature Review Dec 28, 2023
- Orismilast for the treatment of mild to severe hidradenitis suppurativa: Week 16 data from OSIRIS, a Phase 2a, open-label, single-centre, single-arm, dose-finding clinical trial Dec 26, 2023
- Unraveling the Epigenetic Tapestry: Decoding the Impact of Epigenetic Modifications in Hidradenitis Suppurativa Pathogenesis Dec 26, 2023
- A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment Dec 26, 2023
- Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm Dec 22, 2023
- Comparative Transcriptome Analysis of Acne vulgaris, Rosacea, and Hidradenitis Suppurativa Supports High Dose Dietary Zinc as a Therapeutic Agent [Preprint] Dec 4, 2023
- Understanding the bacterial imbalance in Hidradenitis Suppurativa patients: Insights into microbial community shifts and colonization by opportunistic pathogens [Preprint] Nov 13, 2023
- NK and NKT cells in the pathogenesis of Hidradenitis suppurativa: Novel therapeutic strategy through targeting of CD2 [Preprint] Nov 2, 2023
- Hidradenitis Suppurativa Patients Exhibit a Distinctive and Highly Individualized Skin Virome [Preprint] Nov 1, 2023
- JAAD Game Changer: “High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa” Aug 16, 2023
- Hidradenitis Suppurativa and Five Key Vitamins and Minerals Mar 23, 2023
Clinical Trials
- Botulinum Toxin-A for Hidradenitis Suppurativa Feb 1, 2024
- Hidradenitis Suppurativa Phase 2b Pivotal Study of Izokibep Jan 29, 2024
- Randomised, Double-blind, Placebo-controlled, Phase IIb/Phase III Study to Evaluate the Efficacy and Safety of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa Jan 24, 2024
- A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Jan 19, 2024
- A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Jan 18, 2024
- Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients Jan 12, 2024
- A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY® Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa Jan 12, 2024
- A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa Jan 5, 2024
- Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Dec 28, 2023
- Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa Nov 14, 2023
- Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa Oct 10, 2023
- Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa Oct 26, 2022
Funded Projects
Note: This section is almost ready. Expect full project-related coverage by 2/7/2024. (In this context, “Projects” refers specifically to government-funded research projects that are in progress.)